Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma - Wikidata - wikimedia - TriplyDB

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

http://www.wikidata.org/entity/Q33397833

about

Targeted therapies in sarcomas: challenging the challenge Cell Proliferation in Neuroblastoma DIPG in Children - What Can We Learn from the Past?Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Rhabdomyosarcoma: current challenges and their implications for developing therapies.The mTOR signaling pathway as a treatment target for intracranial neoplasms GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis Management of high-grade gliomas in the pediatric patient: Past, present, and future.The challenges and the promise of molecular targeted therapy in malignant gliomas.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Rhabdomyosarcoma of the head and neck in children Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Molecular profiling of childhood cancer: Biomarkers and novel therapies Diffuse intrinsic pontine glioma: poised for progress.Advances in paediatric cancer treatment Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency Comparative transcriptomic analysis reveals the oncogenic fusion protein PAX3-FOXO1 globally alters mRNA and miRNA to enhance myoblast invasion.It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.Neuroblastoma treatment in the post-genomic era.Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors Paediatric and adult malignant glioma: close relatives or distant cousins?Ten challenges in the management of neuroblastoma.Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.Emerging drugs for neuroblastoma.Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.Rhabdomyosarcoma in adults: new perspectives on therapy.Managing teenage/young adult (TYA) brain tumors: a UK perspective.

P2860

Q21285014-0B0CE2DA-C4CD-4800-ABF6-FCAABE2DE887 Q26771708-FB1CBDF2-7EDF-4E6A-8F03-58FFC7EF31D6 Q26777843-01390BBA-9974-4EB6-BD66-17B2979CE492 Q26795742-3988A403-0CEB-4F58-BD5E-D7DEC1ACBE3C Q26825000-C5F36759-B23A-4C6C-A78F-0DBEC0A410C5 Q28070264-82A5ECD3-D38D-4BED-8C9A-8AC581A6584F Q33411585-A8ED3B50-45BF-4872-8AB1-1BF5FC6B1F41 Q33435808-0A945869-82EA-4A49-B1AA-87013007ADE1 Q33438006-028036B2-C756-465C-B2E4-9666DA2C1BD5 Q33442162-12910DE8-2EFB-4868-8B78-8D28264AED65 Q33618884-639284A0-2861-46D7-86CF-3C9C543B0EC0 Q34400242-649227DA-4E16-44E5-AE07-F96B3A6A6102 Q34886859-FB119023-B049-4BFF-8F89-953EFADE1A90 Q35067950-FAFCFE61-15E6-4E49-862A-1D76BE82800A Q35206259-AC6753D8-910D-4E85-BEB2-3421BCB1EF6B Q35214534-C855BCB2-45A1-4332-A402-2103757F1EE1 Q35224485-D374E880-50B9-4D48-BBE5-C20E70145394 Q35648994-113B329F-E7E0-49E8-959A-E71FD53DF7EF Q35850208-5BCD5138-B4CF-4D23-8014-55134EA32FFC Q36142754-60A4C4AE-A087-47CB-931D-8E025C99BCCB Q36250783-D8EA7922-6155-4DF9-9036-21C453D85827 Q36492719-3846DA62-7C62-4638-BCFA-64E7F11F6F4F Q36508630-E4A1D786-076F-4215-BD4B-953E6719C8D8 Q37048013-C07C6550-8D15-4E57-944C-9CE042D09794 Q37150545-42BDA616-D75D-4022-806B-4E89FCD5126E Q37308813-2F6E2BFB-7683-4067-8D36-90D15524ABCC Q37633731-5AA0BEF1-B3F6-479E-B4B9-E93199F32C01 Q37665168-0827ADDD-631C-477E-8983-3456121819F5 Q37733075-6BA20E69-4784-4C2F-B4AF-D5DA4396C505 Q38013990-EA9291FC-00AA-4AA5-B81F-A970847507D6 Q38029366-9CED6996-5535-4C0A-9F08-C8B2BDBA6D8C Q38074880-74DD36D8-671E-4C27-8862-32C613AF79F8 Q38103561-C820F74B-62F2-4DF9-B7E1-61B2C0EFBB58 Q38108399-BC80830A-D8AD-4697-BCC0-A4EC10512390 Q38131047-65028D56-8C4C-4E76-907A-252A52D3B422 Q38233425-B7149F9D-876A-4603-A0DA-ACB3D724BE1B Q38242086-AC935BCF-D72C-4411-9DA6-C1B210DD3A07 Q38474631-ED9E409C-E379-47B2-BEB9-445FFEC0CC20 Q38480485-5D2834C5-11C5-4B4A-90B7-8A1B79295E34 Q38539466-F7C4E90D-7F87-428A-9CA8-89233451A184

P2860

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

http://www.wikidata.org/entity/Q33397833

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@ast

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@en

type

label

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@ast

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@en

prefLabel

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@ast

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@en

P1433

Q33397833-45FC9383-D1A1-495F-ACC2-D67505357CC6

P1476

Q33397833-96A4F61E-52F9-4668-BDC8-40E61F4D9A1C

P2093

Q33397833-2071557E-33CC-4B9C-99CD-EF3AD099609C

Q33397833-38C42E01-067A-460D-8205-9D9DB4D12CAC

Q33397833-8638CDC1-90E0-4B8C-9570-1258BE4D5852

Q33397833-93E60177-2856-48DA-9882-879689DC46E9

Q33397833-944687FA-D285-4CA6-8D02-B220AFE36BF0

Q33397833-9B63A4B6-9708-4575-A4F1-82CAFC059BCD

Q33397833-9D0173FF-A7A3-456E-93CC-5BE2E5B95441

Q33397833-B116EA8D-950D-4039-9744-F0EB0D6ED26E

Q33397833-F2DD15B8-6DD8-4826-9EB5-6BCCB44E7C58

P2860

Q33397833-0288356B-7D1F-445C-8D5C-47AFA4F318FD

Q33397833-0B693221-BC4C-488C-BB84-A4B01A7D6688

Q33397833-0B6B4922-DD4C-4F30-B5D7-2B0CA0B3EB69

Q33397833-0B6B8CFD-BF15-4DA3-8D1C-F0ADEF7B8E03

Q33397833-3A3E7BB7-D827-4267-A4E1-78D26A7F0515

Q33397833-476AE35B-A76B-428A-93E5-BEE4681A3347

Q33397833-4AC574D6-1B21-4EB6-B9DD-B1DB8A444120

Q33397833-4F2CFE21-B4BE-4032-9D9F-0A47D3EA3403

Q33397833-564AB8BB-1510-4142-86F2-5707ACE9D00B

Q33397833-5CA19B56-33ED-4FE8-B5B5-ECA9A51E8C85

P304

Q33397833-26320F32-B019-41D1-B13A-B566E6194227

P31

Q33397833-77EB8C40-02D1-4E46-8946-FA85BCAAF434

P356

Q33397833-985FB275-166C-4429-8B69-C70552F5D9CA

P433

Q33397833-5A3C9B42-4DDE-4223-BD1F-F6254539C138

P478

Q33397833-24D41AFF-4A09-49AD-9E04-33E593700D07

P50

Q33397833-1239B325-B658-4A5B-96C9-270FFF035015

P577

Q33397833-30E0DC5A-0DE9-4DEF-9943-886D1F90FE44

P698

Q33397833-7B13696B-60A6-47B5-AA49-AA2D444DE765

P921

Q33397833-A19361B4-48CC-44EB-88CA-94AF6D9B3CC9

P932

Q33397833-4BF2AF18-E892-4150-881E-4B6F2CC04B5A

P356

J.EJCA.2011.09.021

P1433

European Journal of Cancer

P1476

Phase II trial of temsirolimus ...... oblastoma and rhabdomyosarcoma

@en

P2093

Anna Berkenblit

http://www.w3.org/2001/XMLSchema#string

Birgit Geoerger

http://www.w3.org/2001/XMLSchema#string

Danuta Perek

http://www.w3.org/2001/XMLSchema#string

Jill Clancy

http://www.w3.org/2001/XMLSchema#string

Joseph P Boni

http://www.w3.org/2001/XMLSchema#string

Mizue Krygowski

http://www.w3.org/2001/XMLSchema#string

Revathi Ananthakrishnan

http://www.w3.org/2001/XMLSchema#string

Sheri L Spunt

http://www.w3.org/2001/XMLSchema#string

Stephan Grupp

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of childhood cancer

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Defining the role of mTOR in cancer

The TOR pathway: a target for cancer therapy

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies.

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

P304

253-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2011.09.021

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22033322

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3539305

http://www.w3.org/2001/XMLSchema#string